DALOSIRVAT, SM04554, and SETIPIPRANT all work by inhibiting the production of PGD2, a protein that can interfere with the growth of hair follicles. This is the most common type of hair loss, affecting around 50 million men in the United States. PGD2 is naturally produced in the skin and is thought to be responsible for the inflammation that causes hair loss. Drugs like DALOSIRVAT, SM04554, and SETIPIPRANT inhibit the production of PGD2, protecting hair follicles from the harmful effects of inflammation and encouraging hair growth.
These APIs are applied to the scalp once a day for 6 weeks and were tested in two clinical trials. The first Phase I/IIa exploratory trial showed they are safe and well-tolerated in patients with androgenetic alopecia. The second trial, the Phase IIb study tested the efficacy of the drug and was found to be very effective in slowing or halting hair loss in all subjects who received the treatment for 6 weeks.
The combination of these agents with the active ion of Minoxidil sulfate that instantly inhibits DHT enzymes and selenium sulfide prevents dandruff and other scalp infections that contribute to hair loss making this product a win-win solution to hair loss problems.
Drug Status: Approved
Size: 2.5 Full OZ
Contact us for minimum private label quantity and pricing